News
& Events
News
& Events

News
& Events

Sep 2, 2017 Inversago Pharma’s CEO François Ravenelle will attend RESI Boston event

Inversago Pharma’s CEO François Ravenelle will attend RESI Boston event on September 26th.

Apr 26, 2016 Inversago Pharma announces the execution of license agreement with US NIH’s CB1 inverse agonist technology.

Inversago Pharma annonce la prise d’effet de l’accord d’octroi de licence conclu avec les National Institutes of Health (NIH) des États-Unis concernant leur technologie d’agonistes inverses du CB1.

Oct 28, 2015 National Institutes of Health Notice on Prospective Grant of Exclusive License.

Read more